MX2014004813A - Regimen de dosificacion para un modulador o agonista del receptor s1p. - Google Patents

Regimen de dosificacion para un modulador o agonista del receptor s1p.

Info

Publication number
MX2014004813A
MX2014004813A MX2014004813A MX2014004813A MX2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A MX 2014004813 A MX2014004813 A MX 2014004813A
Authority
MX
Mexico
Prior art keywords
receptor modulator
agonist
dosage regimen
human
patient
Prior art date
Application number
MX2014004813A
Other languages
English (en)
Inventor
Erik Wallstroem
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47022722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014004813A publication Critical patent/MX2014004813A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a un método de tratamiento de la esclerosis múltiple en un paciente mamífero, preferiblemente un ser humano, en necesidad de tal tratamiento, que comprende administrar al humano un modulador o agonista del receptor de S1P de acuerdo con un régimen de dosificación que se determina con referencia al conteo de linfocitos en la sangre del paciente.
MX2014004813A 2011-10-21 2012-10-18 Regimen de dosificacion para un modulador o agonista del receptor s1p. MX2014004813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549847P 2011-10-21 2011-10-21
PCT/EP2012/070692 WO2013057212A1 (en) 2011-10-21 2012-10-18 Dosage regimen for an s1p receptor modulator or agonist

Publications (1)

Publication Number Publication Date
MX2014004813A true MX2014004813A (es) 2014-05-20

Family

ID=47022722

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004813A MX2014004813A (es) 2011-10-21 2012-10-18 Regimen de dosificacion para un modulador o agonista del receptor s1p.

Country Status (17)

Country Link
US (1) US20150218090A1 (es)
EP (1) EP2768494A1 (es)
JP (1) JP2014530835A (es)
KR (1) KR20140084041A (es)
CN (1) CN103889408A (es)
AU (1) AU2012324867B2 (es)
BR (1) BR112014009141A8 (es)
CA (1) CA2852142A1 (es)
CL (1) CL2014000991A1 (es)
IL (1) IL231945A0 (es)
MX (1) MX2014004813A (es)
RU (1) RU2014120411A (es)
SG (2) SG10201602279PA (es)
TN (1) TN2014000132A1 (es)
TW (1) TW201320998A (es)
WO (1) WO2013057212A1 (es)
ZA (1) ZA201402283B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074312A1 (en) * 2014-04-10 2022-10-19 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
EP3168237A1 (en) * 2015-11-10 2017-05-17 Dow Global Technologies LLC High pressure, free radical polymerizations to produce ethylene-based polymers
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
CN115884762A (zh) * 2020-08-20 2023-03-31 南京明德新药研发有限公司 苯乙酮肟类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944026B1 (en) 2002-05-16 2013-06-26 Novartis AG Use of EDG receptor binding agents in cancer
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
CN1816544B (zh) * 2003-05-19 2011-06-08 Irm有限责任公司 免疫抑制剂化合物和组合物
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストの投与レジメン
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
TW200927142A (en) * 2007-10-12 2009-07-01 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
CN105213372A (zh) * 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
BR112012006957A2 (pt) * 2009-09-29 2016-06-14 Novartis Ag regime de dosagem de um modulador de receptor de s1p

Also Published As

Publication number Publication date
KR20140084041A (ko) 2014-07-04
BR112014009141A8 (pt) 2017-06-20
AU2012324867B2 (en) 2015-09-10
CA2852142A1 (en) 2013-04-25
EP2768494A1 (en) 2014-08-27
IL231945A0 (en) 2014-05-28
US20150218090A1 (en) 2015-08-06
CL2014000991A1 (es) 2014-08-22
ZA201402283B (en) 2015-03-25
AU2012324867A1 (en) 2014-05-08
NZ623571A (en) 2016-03-31
RU2014120411A (ru) 2015-11-27
WO2013057212A1 (en) 2013-04-25
CN103889408A (zh) 2014-06-25
BR112014009141A2 (pt) 2017-06-13
TW201320998A (zh) 2013-06-01
SG11201401065RA (en) 2014-09-26
JP2014530835A (ja) 2014-11-20
SG10201602279PA (en) 2016-04-28
TN2014000132A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
EA037351B8 (ru) Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
EA201690738A1 (ru) Ингалятор сухого порошка
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
NZ707377A (en) Combination therapy methods for treating proliferative diseases
BR112012026886A2 (pt) dispositivo de injeção automático usável para distribuição controlada de agentes terapêuticos
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
TN2014000132A1 (en) Dosage regimen for an s1p receptor modulator or agonist
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2014005996A (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
IN2012DN06309A (es)
MY174010A (en) Device for extracorporeal blood treatment
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
BR112014029302A2 (pt) método de redução de peso
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
EA201491046A1 (ru) Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
CY1117605T1 (el) Θεραπεια της ασθενειας crohn me laquinimod